AstraZeneca’s head of research and development has said the UK drugmaker would consider not submitting its Covid-19 vaccine for approval in the US if it finds it is “banging its head against a brick wall indefinitely” with regulators.
英国制药商阿斯利康(AstraZeneca)的研发主管表示，如果该公司发现自己在监管机构那里是在“无限期地用头撞墙”，将考虑不在美国提交新冠病毒疫苗以获批准。
您已阅读7%（314字），剩余93%（4018字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。